Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>IN8Bio is a clinical-stage, oncology-focused biotechnology company using ?d T cells against solid and hematological tumors.</li><li>Its pipeline is built on the DeltEx platform & drug resistant immunotherapy (DRI) technology which have produced clinical candidates targeting leukemia & GBM.</li><li>INB-100 is evaluating leukemia in a Ph1 study, while INB-200 & INB-400 are Ph1 and Ph2 assets evaluating GBM.</li></ul>

IN8Bio is a clinical-stage, oncology-focused biotechnology company using ?d T cells against solid and hematological tumors.Its pipeline is built on the DeltEx platform & drug resistant immunotherapy (DRI) technology which have produced clinical candidates targeting leukemia & GBM.INB-100 is evaluating leukemia in a Ph1 study, while INB-200 & INB-400 are Ph1 and Ph2 assets evaluating GBM.

<ul><li>IN8Bio is a clinical-stage, oncology-focused biotechnology company using ?d T cells against solid and hematological tumors.</li><li>Its pipeline is built on the DeltEx platform & drug resistant immunotherapy (DRI) technology which have produced clinical candidates targeting leukemia & GBM. INB-100 is evaluating leukemia in a Ph1 study, while INB-200 & INB-400 are Ph1 and Ph2 assets evaluating GBM. INB-100 is an allogeneic DeltEx-produced cell therapy for leukemia patients undergoing HSCT transplant.</li><li>Leukemia patients see a high rate of recurrence which may be effectively treated by INB-100.</li></ul>

IN8Bio is a clinical-stage, oncology-focused biotechnology company using ?d T cells against solid and hematological tumors.Its pipeline is built on the DeltEx platform & drug resistant immunotherapy (DRI) technology which have produced clinical candidates targeting leukemia & GBM. INB-100 is evaluating leukemia in a Ph1 study, while INB-200 & INB-400 are Ph1 and Ph2 assets evaluating GBM. INB-100 is an allogeneic DeltEx-produced cell therapy for leukemia patients undergoing HSCT transplant.Leukemia patients see a high rate of recurrence which may be effectively treated by INB-100.

United States

vTv Therapeutics Inc. operates as a clinical-stage pharmaceutical company. The Company focuses on the discovery and development of human therapeutics to fill unmet medical needs. vTv Therapeutics serves customers in the United States.

Alaunos Therapeutics Inc. operates as a clinical stage cellular immuno-oncology company. The Company focuses on the treatment of solid tumors through adoptive TCR-T cell therapy. Alaunos Therapeutics serves customers worldwide.

VBI Vaccines, Inc. is a biopharmaceutical company developing technologies to expand vaccine  protection in large underserved markets. The Company's eVLP vaccine platform allows for the  design of enveloped virus-like particle vaccines that closely mimic the target virus.

Oncocyte Corporation operates as a molecular diagnostics company. The Company offers actionable answers at decision points across the cancer care continuum, as well as focuses on improving patient outcomes by accelerating and optimizing diagnosis and treatment. Oncocyte serves clients in the United States.

Fortress Biotech, Inc. is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. The Company will provide funding and management services to each of the Fortress Companies, and will seek licensing, partnerships, joint ventures and/or public and and private financing for research and development support.

Cue BioPharma, Inc. operates as a bio-technology company. The Company discovers and develops medicines for cancers and autoimmune diseases. Cue BioPharma focuses on design and clinical development of protein biologics, immunology, and immuno-oncology. Cue BioPharma serves customers in the State of Massachusetts.

Bioxcel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical development company. The Company utilizes big data, machine learning, and artificial intelligence to identify the next wave of medicines across neuroscience, immuno-oncology, and related diseases. BioXcel Therapeutics serves customers in the State of Connecticut.

Cortexyme, Inc. operates as a biotech company. The Company develops therapeutics and diagnostics for the treatment of alzheimer disease and other neurodegenerative disorders. Cortexyme serves clients in the State of California.

Aspira Women's Health Inc. operates as a biotech company. The Company develops and discovers testing and treatments for gynecologic issues. Aspira Women's Health serves customers in the State of Texas.

Minerva Neurosciences, Inc. operates as a clinical-stage biopharmaceutical company. The Company develops new therapies to treat central nervous system (CNS) and neuropsychiatric diseases. Minerva Neurosciences serves communities in the United States.

Cynata Therapeutics Ltd is involved in regenerative medicine.  The Company is focused on the commercialization of a stem cell platform.

Genematrix Inc. provides diagnostics & therapeutic solution.  The Company's services are based on Restriction Fragment Mass Polymorphism (RFMP) technology and applied to theranostics, prognosis, and molecular diagnosis.

China Regenerative Medicine International Limited is engaged in research and development of bio-medical and healthcare products, and medical techniques, the provision of the production and sales of tissue engineering products and its related by-products, as well as sales and distribution of medical products and equipment.

General Biologicals Corp. produces molecular diagnostic product. The Company's also offer research development, marketing and servicing of products and solutions for hospitals, medical laboratory and blood bank, and research and industry.

Gene Techno Science Co., Ltd. is a biomedicine company that researches and developes drugs. In addition to drug development, the company also supply the pharmaceutical ingredients.

DNA Link Inc. is a biotechnology company specializing in genomic research technology for rapid analysis of whole genomes.  The Company also provides personalized genomic service which analyze individual's genomic sequence to identify his or her susceptibility to genetic diseases and calculate their risk factors.

DR. Chip Biotechnology Inc. develops biochips, nucleic acid extraction kits, rapid hybridization equipment, biotechnology software, as well as provides diagnostic services.

Original BioMedicals Co., Ltd. is a biotechnology company. The Company develops new drugs and creates drug carriers to enhance or repurpose current drugs.

OptiBiotix Health plc, a life sciences company, engages in the research and development of microbiome modulators in the United Kingdom. The company has a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest, and appetite suppression. Its products under development include novel microbial strains for cholesterol and lipid management; an ingredient formulation, which is scientifically formulated to support and maintain weight loss; and microbiome modulators that enhance the growth of specific microbial species in the human microbiome. The company is based in York, the United Kingdom.

Novacyt SA operates as a specialist in cancer and infectious diseases. The Company sells diagnostic products used in oncology, microbiology, haematology, and serology testing. Novacyt serves hospitals, clinicians, health care providers, and patients worldwide.

IN8bio, Inc. operates as a clinical-stage biotechnology company. The Company focuses on developing therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. IN8bio serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

IN8bio (INAB US)

INAB: INB-100 Update at EHA24 Ole!

IN8Bio is a clinical-stage, oncology-focused biotechnology company using ?d T cells against solid and hematological tumors. Its pipeline is built...

Zacks Small Cap Research

INAB: INB-200 Update at ASCO24

IN8Bio is a clinical-stage, oncology-focused biotechnology company using ?d T cells against solid and hematological tumors. Its pipeline is built...

Zacks Small Cap Research

INAB: 1Q:24 Results

IN8Bio is a clinical-stage, oncology-focused biotechnology company using ?d T cells against solid and hematological tumors. Its pipeline is built...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)